Niyogin Fintech Regulatory Approval

Other Announcement

Niyogin Fintech Other Announcement

Niyogin Fintech Ltd filed its quarterly shareholding pattern as per Regulation 31(1)(b). This is a standard periodic compliance disclosure.

Debt & Borrowing

Niyogin Fintech Debt & Borrowing

Niyogin Fintech Ltd confirmed the interest payment status for its 12.60% non-convertible debentures due on October 19, 2026.

Debt & Borrowing

Niyogin Fintech Debt & Borrowing: ₹0.33 Cr

Niyogin Fintech Ltd has confirmed the successful payment of interest on its non-convertible debentures. The payment of Rs.0.33 Crore was made on the due date.

Value

₹0.33 Cr

Annual General Meeting

Niyogin Fintech Annual General Meeting

Niyogin Fintech issued an AGM notice for September 23, 2026. Agenda includes financial adoption and the ₹11.75 Crore stake sale of subsidiary Investdirect Capital.

Value

₹11.75 Cr

Merger & Restructuring

Niyogin Fintech Merger & Restructuring

Niyogin Fintech has scheduled court-convened meetings for shareholders and creditors on October 30, 2026, to vote on its composite scheme of arrangement and amalgamation.

Management Change

Niyogin Fintech Management Change

Abhishek Thakkar has resigned as President and Chief Financial Officer of Niyogin Fintech Limited. His resignation is effective from September 25, 2026.

Regulatory ApprovalShalby Ltd SHALBYAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Shalby Regulatory Approval

Shalby Hospital, Jabalpur received CMHO permission to resume normal operations, including patient admissions, on its previously affected floor. The hospital has now fully resumed healthcare services.

Regulatory ApprovalElantas Beck India Ltd ELANTASAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Elantas Beck India Regulatory Approval

Elantas Beck India's GPCB permanently revoked the closure direction on its Ankleshwar plant. The facility can keep operating, subject to compliance conditions.

Regulatory ApprovalKalyani Cast-Tech Ltd 544023Alfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Kalyani Cast-Tech Regulatory Approval

Kalyani Cast-Tech received RDSO Stage-I concept design approval for its new container-carrying wagon under PWDA. Stage-II detailed design approval is still required, subject to dynamics simulation conditions.

Regulatory ApprovalMukka Proteins Ltd MUKKAAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Mukka Proteins Regulatory Approval

Mukka Proteins received a US FDA facility registration certificate, valid October 1, 2026 to December 31, 2027. The company says the registration supports its engagement with US customers and markets.

Execution

October 1, 2026 to December 31, 2027

Regulatory ApprovalCanara Bank CANBKAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Canara Bank Regulatory Approval

Canara Bank received RBI permission to exercise the call option on its Basel III AT1 bonds (ISIN INE476A08134) of Rs.1,500 Crore. The bank is now in process of exercising the call as per the issue terms.

Value

₹1,500 Cr

Regulatory ApprovalAlembic Pharmaceuticals Ltd APLLTDAlfa AlertAn Alfa Alert is ALFA Finder's top-priority alert: filings that can move a stock, such as orders, fund raises and approvals, sent to subscribers on Telegram within seconds of reaching the exchange.

Alembic Pharmaceuticals Regulatory Approval

Alembic Pharmaceuticals received USFDA final approval for Valganciclovir for Oral Solution, 50 mg/mL. This adds to its cumulative 247 USFDA ANDA approvals.